Published in J Parasitol on August 01, 2006
Substance P causes seizures in neurocysticercosis. PLoS Pathog (2012) 0.91
Mechanisms regulating monocyte CXCL8 secretion in neurocysticercosis and the effect of antiparasitic therapy. J Immunol (2010) 0.78
Retention in care: a challenge to survival with HIV infection. Clin Infect Dis (2007) 10.66
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08
Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev (2002) 3.37
Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care (2005) 2.64
The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.43
Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr (2003) 2.33
Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia (2014) 2.11
New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg (2005) 2.10
Neuroendoscopic diagnosis of central nervous system histoplasmosis with basilar arachnoiditis. World Neurosurg (2011) 2.05
An updated review on Cryptosporidium and Giardia. Gastroenterol Clin North Am (2006) 2.05
Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb) (2007) 1.95
Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis (2012) 1.95
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett (2010) 1.82
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74
Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis (2005) 1.72
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev (2016) 1.66
Cord factor trehalose 6,6'-dimycolate (TDM) mediates trafficking events during mycobacterial infection of murine macrophages. Microbiology (2003) 1.55
Multiple roles of cord factor in the pathogenesis of primary, secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary disease. Ann Clin Lab Sci (2006) 1.53
A positive enzyme-linked immunoelectrotransfer blot assay result for a patient without evidence of cysticercosis. Clin Infect Dis (2002) 1.49
Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg (2009) 1.41
Trehalose 6,6'-dimycolate and lipid in the pathogenesis of caseating granulomas of tuberculosis in mice. Am J Pathol (2006) 1.35
Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg (2005) 1.30
Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg (2010) 1.29
Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis (2010) 1.29
Zoonotic larval cestode infections: neglected, neglected tropical diseases? PLoS Negl Trop Dis (2009) 1.26
A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis (2013) 1.23
Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis (2009) 1.23
Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol (2007) 1.23
Influence of trehalose 6,6'-dimycolate (TDM) during mycobacterial infection of bone marrow macrophages. Microbiology (2002) 1.22
Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) (2011) 1.19
Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab (2002) 1.18
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis (2007) 1.17
Cyclic mechanical strain inhibits skeletal myogenesis through activation of focal adhesion kinase, Rac-1 GTPase, and NF-kappaB transcription factor. FASEB J (2004) 1.16
Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection. Antimicrob Agents Chemother (2005) 1.15
A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6'-dimycolate induced granulomatous response. Microbiology (2008) 1.15
A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential. Infect Immun (2004) 1.12
Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis (2003) 1.12
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett (2012) 1.12
Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect (2007) 1.10
Transendothelial migration of leukocytes carrying infectious HIV-1: an indicator of adverse prognosis. AIDS (2002) 1.08
Cestode infestations: hydatid disease and cysticercosis. Infect Dis Clin North Am (2012) 1.05
Foxp3+ regulatory T cells in antiretroviral-naive HIV patients. AIDS (2006) 1.04
A humanized mouse model of tuberculosis. PLoS One (2013) 1.03
Mycobacterial glycolipid trehalose 6,6'-dimycolate-induced hypersensitive granulomas: contribution of CD4+ lymphocytes. Microbiology (2007) 1.02
Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect (2008) 1.02
Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. Am J Trop Med Hyg (2003) 1.01
Failure of CD1D-/- mice to elicit hypersensitive granulomas to mycobacterial cord factor trehalose 6,6'-dimycolate. J Interferon Cytokine Res (2004) 0.99
Interleukin-15 activates human natural killer cells to clear the intestinal protozoan cryptosporidium. J Infect Dis (2005) 0.99
Enteropathogens and chronic illness in returning travelers. N Engl J Med (2013) 0.99
Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int Immunopharmacol (2005) 0.98
Neurocysticercosis in the United States. Pathog Glob Health (2012) 0.98
Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response. Glycoconj J (2008) 0.95
Immunopathology of postprimary tuberculosis: increased T-regulatory cells and DEC-205-positive foamy macrophages in cavitary lesions. Clin Dev Immunol (2010) 0.95
TB research at UT-Houston--a review of cord factor: new approaches to drugs, vaccines and the pathogenesis of tuberculosis. Tuberculosis (Edinb) (2009) 0.95
Rapid detection of oleander poisoning by Digoxin III, a new Digoxin assay: impact on serum Digoxin measurement. Am J Clin Pathol (2008) 0.95
Cryptosporidium infection of human intestinal epithelial cells increases expression of osteoprotegerin: a novel mechanism for evasion of host defenses. J Infect Dis (2008) 0.94
Intestinal immune response to human Cryptosporidium sp. infection. Infect Immun (2007) 0.93
Human CD8(+) T cells clear Cryptosporidium parvum from infected intestinal epithelial cells. Am J Trop Med Hyg (2010) 0.92
Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. Innate Immun (2009) 0.92
Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med Microbiol Immunol (2007) 0.91
Sequential expression of the neuropeptides substance P and somatostatin in granulomas associated with murine cysticercosis. Infect Immun (2002) 0.91
Advances in the diagnosis and management of neurocysticercosis. Expert Rev Anti Infect Ther (2006) 0.90
Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages. Biochimie (2008) 0.90
Substance P is required for the pathogenesis of EMCV infection in mice. Int J Clin Exp Med (2009) 0.90
Seropositive human subjects produce interferon gamma after stimulation with recombinant Cryptosporidium hominis gp15. Am J Trop Med Hyg (2007) 0.90
Lactoferrin in health and disease. Postepy Hig Med Dosw (Online) (2007) 0.90
CD3+ cells transfer the hypersensitive granulomatous response to mycobacterial glycolipid trehalose 6,6'-dimycolate in mice. Microbiology (2006) 0.90
Treatment of cryptosporidiosis. Expert Rev Anti Infect Ther (2009) 0.89
Substance P is associated with heart enlargement and apoptosis in murine dilated cardiomyopathy induced by Taenia crassiceps infection. J Parasitol (2007) 0.89
Immune modulation of macrophage pro-inflammatory response by goldenseal and Astragalus extracts. J Med Food (2008) 0.89
Nitazoxanide: an important advance in anti-parasitic therapy. Am J Trop Med Hyg (2003) 0.88
Epileptogenic activity of granulomas associated with murine cysticercosis. Exp Neurol (2003) 0.88
Burden of Fasciola hepatica Infection among children from Paucartambo in Cusco, Peru. Am J Trop Med Hyg (2012) 0.88
A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice. Vaccine (2009) 0.87
Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis. Vaccine (2007) 0.87
A defect in the synthesis of Interferon-γ by the T cells of Complement-C5 deficient mice leads to enhanced susceptibility for tuberculosis. Tuberculosis (Edinb) (2011) 0.87
Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection. Infect Immun (2013) 0.87
Cytokine production by non-adherent mouse splenocyte cultures to Echinacea extracts. Clin Chim Acta (2004) 0.86
Workshop report: Developing an international collaborative research network in neurocysticercosis and epilepsy. Epilepsia (2009) 0.86
Cryopreservation modulates the detection of regulatory T cell markers. Cytometry B Clin Cytom (2011) 0.86
Lactoferrin modulation of BCG-infected dendritic cell functions. Int Immunol (2009) 0.86
Neurocysticercosis in the HIV era: a case report and review of the literature. Am J Trop Med Hyg (2007) 0.85
New developments in epidemiology, diagnosis, and treatment of fascioliasis. Curr Opin Infect Dis (2012) 0.85
Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect (2004) 0.84
Characterization of excretory/secretory endopeptidase and metallo-aminopeptidases from Taenia crassiceps metacestodes. J Parasitol (2005) 0.84
Lactoferrin modulation of antigen-presenting-cell response to BCG infection. Postepy Hig Med Dosw (Online) (2007) 0.84
Substance P is responsible for physiological alterations such as increased chloride ion secretion and glucose malabsorption in cryptosporidiosis. Infect Immun (2006) 0.83
Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology. Tuberculosis (Edinb) (2011) 0.83
Travelers' diarrhea: an update on susceptibility, prevention, and treatment. Curr Gastroenterol Rep (2008) 0.83
Lactoferrin enhances efficacy of the BCG vaccine: comparison between two inbred mice strains (C57BL/6 and BALB/c). Tuberculosis (Edinb) (2009) 0.83
Substance P signaling contributes to granuloma formation in Taenia crassiceps infection, a murine model of cysticercosis. J Biomed Biotechnol (2010) 0.82
High levels of CXCL10 are produced by intestinal epithelial cells in AIDS patients with active cryptosporidiosis but not after reconstitution of immunity. Infect Immun (2006) 0.82
Normalization of FoxP3(+) regulatory T cells in response to effective antiretroviral therapy. J Infect Dis (2010) 0.82
Lactoferrin Augmentation of the BCG Vaccine Leads to Increased Pulmonary Integrity. Tuberc Res Treat (2011) 0.81
Comparing efficacy of BCG/lactoferrin primary vaccination versus booster regimen. Tuberculosis (Edinb) (2011) 0.81